Sanofi-Aventis, Oxford BioMedica enter cancer treatment collaboration

Share this article:
Sanofi-Aventis and UK gene-therapy developer Oxford BioMedica, have announced a joint-collaboration agreement to develop and market the pipeline cancer treatment TroVax. Under terms of the deal, Sanofi-Aventis will pay Oxford BioMedica, the owner of TroVax, up to $690 million if all development and registration targets are met for certain uses, the companies said. Additional payments will be made to Oxford BioMedica if regulatory milestones are achieved in other cancer types. Oxford BioMedica will receive an initial payment of $39 million and further payments of $25 million as targets are reached TroVax is Oxford BioMedica’s main cancer immunotherapy. Early research suggests TroVax has potential for applications in a wide range of solid tumors, including renal, colorectal, lung, breast and prostate cancer. A Phase III trial in renal cancer is ongoing. Both companies will co-fund the renal cancer study, while Sanofi-Aventis will fund all future research, development, regulatory and marketing. Oxford BioMedica has an option to develop TroVax for other cancer types in exchange for enhanced financial returns under terms where Sanofi-Aventis would keep all commercial rights.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...